AntÃ³nio LÃ³pez-BeltrÃ¡n

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2741549/publications.pdf

Version: 2024-02-01

617	21,246	9786	18130
papers	citations	73 h-index	120 g-index

665	665	665	16187
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Human Pathology, 2023, 133, 56-75.	2.0	12
2	International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. European Urology Focus, 2022, 8, 438-446.	3.1	20
3	Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles. Pathology Research and Practice, 2022, 229, 153737.	2.3	0
4	T1 bladder carcinoma with variant histology: pathological features and clinical significance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 989-998.	2.8	15
5	Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. European Urology Oncology, 2021, 4, 784-791.	5.4	24
6	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. European Urology Focus, 2021, 7, 955-963.	3.1	13
7	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. European Urology Oncology, 2021, 4, 331-333.	5.4	5
8	Re: Alfonso GÃ³mez de LiaÃ±o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Antiâ€“PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269â€“76. European Urology, 2021, 79, e17-e19.	1.9	1
9	Exciting experiences in the â€˜Rocky road to digital diagnosticsâ€™. Journal of Clinical Pathology, 2021, 74, 5-6.	2.0	4
10	Stage T1 bladder cancer: diagnostic criteria and pitfalls. Pathology, 2021, 53, 67-85.	0.6	11
11	Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. European Urology Oncology, 2021, 4, 558-569.	5.4	11
12	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers, 2021, 13, 131.	3.7	153
13	Predicting future cancer burden in the United States by artificial neural networks. Future Oncology, 2021, 17, 159-168.	2.4	8
14	An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opinion on Investigational Drugs, 2021, 30, 245-251.	4.1	13
15	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. Translational Andrology and Urology, 2021, 10, 1581-1587.	1.4	3
16	Towards a new WHO classification of renal cell tumor: what the clinician needs to knowâ€”a narrative review. Translational Andrology and Urology, 2021, 10, 1506-1520.	1.4	34
17	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. Cancers, 2021, 13, 1424.	3.7	21
18	Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now. Translational Andrology and Urology, 2021, 10, 1499-1505.	1.4	6

#	Article	IF	Citations
19	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. Translational Andrology and Urology, 2021, 10, 1562-1568.	1.4	2
20	Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. Modern Pathology, 2021, 34, 1384-1391.	5.5	9
21	Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. Pathology Research and Practice, 2021, 219, 153377.	2.3	0
22	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. Translational Andrology and Urology, 2021, 10, 1530-1540.	1.4	10
23	The Wide Spectrum of Oncocytic Changes and Tumors in the Kidney: Splitting and Lumping. Pathobiology, 2021, 88, 1-4.	3.8	0
24	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. International Journal of Molecular Sciences, 2021, 22, 5522.	4.1	12
25	RE: Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer, by Jones TD and Cheng L, https://doi.org/10.1016/j.urolonc.2020.12.007 (Low grade papillary intra-urothelial neoplasia). Urologic Oncology: Seminars and Original Investigations, 2021, 39, 308-309.	1.6	0
26	An update on immunotherapy in uro-oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 229-233.	0.7	2
27	Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489â€“91. European Urology, 2021, 79, e172-e173.	1.9	1
28	The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. Archives of Pathology and Laboratory Medicine, 2021, 145, 1049-1050.	2.5	1
29	Digital whole mount sections of the prostate: heading towards new ways of communicating with clinicians and patients without microscope. Minerva Urology and Nephrology, 2021, , .	2.5	1
30	Molecular pathology of urothelial carcinoma. Human Pathology, 2021, 113, 67-83.	2.0	24
31	Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. Cancers, 2021, 13, 3471.	3.7	9
32	Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes BrÃ¼ndl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Nonâ€“muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Nonâ€“muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182â€“91. European Urology Oncology, 2021, 4, 671-673.	5.4	1
33	Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009. European Urology, 2021, 80, e81-e82.	1.9	0
34	Fluorescence In Situ Hybridization (FISH) Detection of Chromosomal 12p Anomalies in Testicular Germ Cell Tumors. Methods in Molecular Biology, 2021, 2195, 49-63.	0.9	5
35	Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy. Cells, 2021, 10, 20.	4.1	4
36	Whatâ€™s the future in uropathology. Urologia, 2021, 88, 265-266.	0.7	0

#	Article	IF	Citations
37	Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. Methods in Molecular Biology, 2021, 2195, 31-47.	0.9	6
38	Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis. Cancers, 2021, 13, 5500.	3.7	16
39	Mesonephric (Wolffian-derived) Adenocarcinoma of the Female Urethra. American Journal of Surgical Pathology, 2021, 45, 543-549.	3.7	5
40	Artificial intelligence and prostate cancer: Advances and challenges. Urologia, 2021, , 039156032110624.	0.7	1
41	Liquid biopsies in urological cancers: what we need to know before starting using them. Expert Review of Molecular Diagnostics, 2020, 20, 135-139.	3.1	5
42	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27â€“30. European Urology, 2020, 77, e100-e102.	1.9	0
43	Prostate cancer pathology: What has changed in the last 5 years. Urologia, 2020, 87, 3-10.	0.7	6
44	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Expert Review of Molecular Diagnostics, 2020, 20, 207-217.	3.1	5
45	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Review of Molecular Diagnostics, 2020, 20, 255-264.	3.1	14
46	Nonneoplastic Disorders of the Urinary Bladder. , 2020, , 195-229.e11.		2
47	Neoplasms of the Urinary Bladder. , 2020, , 230-321.e19.		3
48	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 141-150.	3.1	14
49	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Review of Molecular Diagnostics, 2020, 20, 231-243.	3.1	24
50	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers, 2020, 12, 84.	3.7	22
51	Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy, 2020, 12, 1257-1268.	2.0	6
52	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Review of Anticancer Therapy, 2020, 20, 755-763.	2.4	14
53	Is There a Role for Immunotherapy in Prostate Cancer?. Cells, 2020, 9, 2051.	4.1	65
54	Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. Journal of Clinical Pathology, 2020, 73, 695-696.	2.0	25

#	Article	IF	Citations
55	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells, 2020, 9, 2653.	4.1	98
56	Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. European Urology, 2020, 78, 478-481.	1.9	8
57	PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. International Journal of Biological Markers, 2020, 35, 82-90.	1.8	2
58	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers, 2020, 12, 1449.	3.7	72
59	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. European Urology, 2020, 78, 114-116.	1.9	4
60	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells, 2020, 9, 1495.	4.1	8
61	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. Cells, 2020, 9, 1522.	4.1	6
62	Epigenetic modulations and lineage plasticity in advanced prostate cancer. Annals of Oncology, 2020, 31, 470-479.	1.2	103
63	A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. Journal of Clinical Medicine, 2020, 9, 605.	2.4	7
64	Renal Cell Carcinoma: genomic landscape and clinical implications. Expert Review of Precision Medicine and Drug Development, 2020, 5, 95-100.	0.7	1
65	Re: Maria Chiara Sighinolfi, Bernardo Roccoâ€™s Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871. European Urology, 2020, 77, e122-e127.	1.9	0
66	Immunotherapy for urothelial cancer: from the diagnostic pathologistâ€™s point of view. Expert Opinion on Biological Therapy, 2020, 20, 539-544.	3.1	9
67	Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. Future Oncology, 2020, 16, 75-80.	2.4	11
68	Molecular diagnostics in uro-oncology. Expert Review of Molecular Diagnostics, 2020, 20, 117-121.	3.1	4
69	Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 111-120.	2.8	24
70	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells, 2020, 9, 1073.	4.1	34
71	pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 3-16.	2.8	8
72	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. Current Drug Targets, 2020, 21, 1463-1475.	2.1	10

#	Article	IF	Citations
73	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. Current Drug Targets, 2020, 21, 1664-1671.	2.1	12
74	Urinary Tract Adenocarcinoma. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
75	Staging and Reporting of Renal Cell Carcinomas. , 2020, , 423-436.		0
76	Specimen Handling: Radical and Partial Nephrectomy Specimens. , 2020, , 411-422.		0
77	Urothelial Carcinoma, Micropapillary Type. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
78	Urothelial Carcinoma, Nested Type. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
79	Urothelial Carcinoma, Invasive. Encyclopedia of Pathology, 2020, , 1-7.	0.0	0
80	Urinary Tract Small Cell Neuroendocrine Carcinoma. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
81	Bladder Cloacal Extrophy. Encyclopedia of Pathology, 2020, , 20-22.	0.0	0
82	Papillary Urothelial Carcinoma. Encyclopedia of Pathology, 2020, , 252-255.	0.0	0
83	Urothelial Carcinoma, Plasmacytoid Type. Encyclopedia of Pathology, 2020, , 486-489.	0.0	0
84	Paratesticular well-differentiated liposarcoma initially diagnosed as fibrous pseudotumour. Indian Journal of Pathology and Microbiology, 2020, 63, 53.	0.2	1
85	Urinary Tract Pure Squamous Cell Carcinoma. Encyclopedia of Pathology, 2020, , 445-448.	0.0	0
86	Cystitis After Radiation. Encyclopedia of Pathology, 2020, , 49-51.	0.0	0
87	Urothelial Carcinoma, Lymphoepithelioma-Like Type. Encyclopedia of Pathology, 2020, , 477-479.	0.0	0
88	Urothelial Carcinoma, Poorly Differentiated. Encyclopedia of Pathology, 2020, , 489-491.	0.0	0
89	Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Type. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
90	Urothelial Carcinoma, Micropapillary Type. Encyclopedia of Pathology, 2020, , 481-484.	0.0	0

#	Article	IF	Citations
91	Urothelial Tumors in Children and Young Adults. Encyclopedia of Pathology, 2020, , 498-501.	0.0	0
92	Inverted Urothelial Papilloma. Encyclopedia of Pathology, 2020, , 158-161.	0.0	0
93	Pathology of the Benign and Malignant Diseases of the Prostate. , 2020, , 1-12.		0
94	Urinary Tract Small Cell Neuroendocrine Carcinoma. Encyclopedia of Pathology, 2020, , 448-451.	0.0	0
95	Urothelial Carcinoma, Lipid-Rich Type. Encyclopedia of Pathology, 2020, , 475-477.	0.0	0
96	Mucinous Metaplasia. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
97	Urothelial Tumors in Children and Young Adults. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
98	Urothelial Carcinoma, Nested Type. Encyclopedia of Pathology, 2020, , 484-486.	0.0	0
99	Prostatic Acinar Adenocarcinoma, Sarcomatoid Variant. Encyclopedia of Pathology, 2020, , 319-322.	0.0	0
100	Papillary Urothelial Neoplasm of Low Malignant Potential. Encyclopedia of Pathology, 2020, , 255-256.	0.0	0
101	Mucinous Metaplasia. Encyclopedia of Pathology, 2020, , 211-212.	0.0	0
102	Urachal Carcinoma. Encyclopedia of Pathology, 2020, , 430-433.	0.0	0
103	Urothelial Carcinoma, Giant Cell Type. Encyclopedia of Pathology, 2020, , 468-469.	0.0	0
104	Urinary Tract, Normal Histology. Encyclopedia of Pathology, 2020, , 456-460.	0.0	0
105	Urethral Polyp, Prostatic Type. Encyclopedia of Pathology, 2020, , 437-438.	0.0	0
106	Urothelial Carcinoma with Divergent Differentiation. Encyclopedia of Pathology, 2020, , 463-466.	0.0	0
107	Urinary Tract, Normal Histology. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
108	Papillary Urothelial Carcinoma. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0

#	Article	IF	Citations
109	Perivascular Epithelioid Cell Tumor. Encyclopedia of Pathology, 2020, , 298-299.	0.0	0
110	Cystitis, Cystic, Glandularis, and Proliferative. Encyclopedia of Pathology, 2020, , 51-53.	0.0	0
111	Urothelial Carcinoma, Sarcomatoid Type. Encyclopedia of Pathology, 2020, , 491-493.	0.0	0
112	Urothelial Carcinoma In Situ. Encyclopedia of Pathology, 2020, , 460-463.	0.0	0
113	Urothelial Carcinoma with Divergent Differentiation. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
114	Urinary Tract Adenocarcinoma. Encyclopedia of Pathology, 2020, , 439-443.	0.0	0
115	Urethral Caruncle. Encyclopedia of Pathology, 2020, , 436-437.	0.0	0
116	Urothelial Carcinoma, Invasive. Encyclopedia of Pathology, 2020, , 469-475.	0.0	0
117	Renal Cell Carcinoma, Unclassified. Encyclopedia of Pathology, 2020, , 342-344.	0.0	0
118	Cystitis After Chemotherapy. Encyclopedia of Pathology, 2020, , 47-49.	0.0	0
119	Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Type. Encyclopedia of Pathology, 2020, , 466-467.	0.0	0
120	Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World Journal of Urology, 2019, 37, 107-114.	2.2	50
121	Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?. European Urology, 2019, 75, 32-34.	1.9	3
122	Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Future Oncology, 2019, 15, 2199-2202.	2.4	14
123	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. Human Pathology, 2019, 93, 6-15.	2.0	3
124	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy, 2019, 11, 1507-1521.	2.0	17
125	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. Cancers, 2019, 11, 1225.	3.7	15
126	Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 735-744.	2.8	3

#	Article	IF	Citations
127	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. Therapeutic Advances in Urology, 2019, 11, 175628721881537.	2.0	7
128	MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. Modern Pathology, 2019, 32, 1666-1674.	5.5	13
129	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers, 2019, 11, 830.	3.7	29
130	Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 445-455.	2.8	38
131	Expression of miRâ€100 and miRâ€138 as prognostic biomarkers in nonâ€muscleâ€invasive bladder cancer. Apmis, 2019, 127, 545-553.	2.0	20
132	Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667â€“75. European Urology, 2019, 76, e69-e72.	1.9	6
133	Editorial: Emerging Biomarkers in Genitourinary Tumors. Frontiers in Oncology, 2019, 9, 326.	2.8	4
134	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2019, 75, 453-467.	2.9	3
135	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Frontiers in Oncology, 2019, 9, 228.	2.8	20
136	Microbiome and Cancers, With Focus on Genitourinary Tumors. Frontiers in Oncology, 2019, 9, 178.	2.8	20
137	Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate. Molecular Carcinogenesis, 2019, 58, 1272-1278.	2.7	5
138	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clinical Drug Investigation, 2019, 39, 503-519.	2.2	26
139	The Human Microbiota and Prostate Cancer: Friend or Foe?. Cancers, 2019, 11, 459.	3.7	38
140	Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538â€“40. European Urology, 2019, 75, e162-e163.	1.9	2
141	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers, 2019, 11, 196.	3.7	23
142	â™,The Prostatic Utricle and Endometrioid Prostate Cancer. , 2019, , 123-127.		0
143	â™,â™€ Cystic Lesions of the Prostate and Lower Genitourinary Tract versus Female Gynecologic Tract Lesions: Similarities and Differences. , 2019, , 128-139.		0
144	â™,â™€Ectopic Prostatic Tissue. , 2019, , 145-149.		0

#	Article	IF	Citations
145	â™,â™€ Prostate and Breast Pathology: Similarities and Differences. , 2019, , 155-170.		1
146	â™,â™€ Clear Cell Tumors of the Kidney and the Gynecologic Tract. , 2019, , 173-188.		0
147	â™,â™€Similarities and Differences in Neuroendocrine Tumors of the Male and Female Genital Tracts and Urinary Tract. , 2019, , 233-244.		0
148	â™,â™€ Transitional Cell Tumors of the Bladder. , 2019, , 254-273.		0
149	â™,â™€ Micropapillary Urothelial Carcinoma of the Bladder versus Gynecologic Tract Carcinomas with Micropapillary Features: Similarities and Differences. , 2019, , 278-282.		0
150	â™,â™€ Pathology of the Female and Male Urethra. , 2019, , 285-303.		0
151	â™,â™€ MÃ¼llerian Lesions of the Bladder: Endometriosis, Endosalpingiosis, Endocervicosis, and MÃ¼llerianosis. , 2019, , 304-309.		0
152	â™,â™€Clear Cell Carcinoma of the Urinary Tract vs. Clear Cell Carcinoma of the Ovary: Similarities and Differences. , 2019, , 310-315.		0
153	â™,â™€Cystic and Solid Tumors of the Urachus vs. Gynecologic Tract Tumors: Similarities and Differences. , 2019, , 316-330.		0
154	â™,â™€Secondary Tumors of the Male and Female Genital Tracts and Urinary Tract: Similarities and Differences. , 2019, , 397-410.		0
155	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. Annals of Translational Medicine, 2019, 7, S137-S137.	1.7	9
156	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). Journal of Clinical Pathology, 2019, 72, 573-578.	2.0	4
157	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. International Journal of Molecular Sciences, 2019, 20, 5683.	4.1	26
158	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy, 2019, 17, 917-927.	1.5	3
159	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureterâ€"Nephroureterectomy and Ureterectomy Specimens. American Journal of Surgical Pathology, 2019, 43, e1-e12.	3.7	5
160	Staging of bladder cancer. Histopathology, 2019, 74, 112-134.	2.9	117
161	Variants and new entities of bladder cancer. Histopathology, 2019, 74, 77-96.	2.9	120
162	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. Journal of Clinical Pathology, 2019, 72, 135-139.	2.0	28

#	Article	IF	Citations
163	Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589â€“97. Eur Urol 2018;74:525â€“6. European Urology, 2019, 75, e110-e113.	1.9	3
164	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells, 2019, 8, 43.	4.1	38
165	Histopathologic challenges: The second OPINION issue. European Journal of Surgical Oncology, 2019, 45, 12-15.	1.0	8
166	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (<scp>ICCR</scp>). Histopathology, 2019, 74, 377-390.	2.9	14
167	PD-L1 assessment in urothelial carcinoma: a practical approach. Annals of Translational Medicine, 2019, 7, 690-690.	1.7	77
168	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. Current Drug Metabolism, 2019, 20, 305-312.	1.2	11
169	Urinary Tract Pure Squamous Cell Carcinoma. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
170	Urothelial Carcinoma: Lipid-Rich Type. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0
171	Cystitis After Chemotherapy. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
172	Prostatic Acinar Adenocarcinoma, Sarcomatoid Variant. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
173	Urothelial Carcinoma, Lymphoepithelioma-Like Type. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
174	Urothelial Carcinoma in Situ. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
175	Perivascular Epithelioid Cell Tumor. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0
176	Cystitis After Radiation. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
177	Urothelial Carcinoma, Sarcomatoid Type. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
178	Urothelial Carcinoma, Giant Cell Type. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0
179	Urachal Carcinoma. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
180	Renal Cell Carcinoma, Unclassified. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0

#	Article	IF	Citations
181	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian Journal of Andrology, 2019, 21, 19.	1.6	2
182	Urothelial Carcinoma, Plasmacytoid Type. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
183	Bladder Cloacal Extrophy. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
184	Papillary Urothelial Neoplasm of Low Malignant Potential. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
185	Inverted Urothelial Papilloma. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
186	Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 189-190.	3.9	3
187	Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Annals of Translational Medicine, 2019, 7, S194-S194.	1.7	1
188	Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy. European Urology, 2018, 73, 978-980.	1.9	0
189	Intraoperative Consultation and Macroscopic Handling. American Journal of Surgical Pathology, 2018, 42, e33-e43.	3.7	16
190	Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 451-460.	2.8	9
191	Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treatment Reviews, 2018, 64, 11-20.	7.7	76
192	Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. Future Oncology, 2018, 14, 277-290.	2.4	19
193	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. Journal of Clinical Pathology, 2018, 71, 467-471.	2.0	6
194	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 685-693.	2.4	19
195	Iatrogenic pathology of the urinary bladder. Seminars in Diagnostic Pathology, 2018, 35, 218-227.	1.5	15
196	From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score. European Urology, 2018, 73, 684-686.	1.9	5
197	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. European Urology Focus, 2018, 4, 880-888.	3.1	25
198	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Seminars in Cancer Biology, 2018, 52, 216-227.	9.6	14

#	Article	IF	Citations
199	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern Pathology, 2018, 31, 24-38.	5.5	324
200	Quick steps toward precision medicine in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2018, 3, 283-285.	0.7	0
201	Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. Expert Review of Molecular Diagnostics, 2018, 18, 1021-1028.	3.1	8
202	The Identification of Immunological Biomarkers in Kidney Cancers. Frontiers in Oncology, 2018, 8, 456.	2.8	40
203	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. Frontiers in Oncology, 2018, 8, 653.	2.8	53
204	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Frontiers in Oncology, 2018, 8, 397.	2.8	20
205	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-8.	2.2	63
206	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. Critical Reviews in Oncology/Hematology, 2018, 131, 1-6.	4.4	10
207	Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma. Apmis, 2018, 126, 705-709.	2.0	15
208	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. International Journal of Biological Markers, 2018, 33, 331-334.	1.8	10
209	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. Frontiers in Oncology, 2018, 8, 221.	2.8	24
210	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncology, 2018, 14, 2559-2564.	2.4	6
211	Re: Isabel Rauscher, Charlotte DÃ¼wel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigenâ€“ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656â€“61. European Urology, 2018, 74, e141-e144.	1.9	3
212	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treatment Reviews, 2018, 68, 80-85.	7.7	27
213	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Review of Molecular Diagnostics, 2018, 18, 645-655.	3.1	20
214	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. World Journal of Urology, 2017, 35, 517-526.	2.2	16
215	TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. European Urology, 2017, 71, 497-498.	1.9	35
216	TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. Future Oncology, 2017, 13, 705-714.	2.4	22

#	Article	IF	Citations
217	Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 401-414.	3.4	28
218	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. Future Oncology, 2017, 13, 1105-1114.	2.4	4
219	Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with theNAB2-STAT6fusion gene. Journal of Clinical Pathology, 2017, 70, 508-514.	2.0	20
220	Lymphoepithelioma-like carcinoma of the upper urinary tract. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 703-709.	2.8	22
221	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790â€“807. European Urology, 2017, 72, e139-e141.	1.9	1
222	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Review of Molecular Diagnostics, 2017, 17, 781-789.	3.1	9
223	A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. Pathology Research and Practice, 2017, 213, 804-808.	2.3	10
224	Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738â€“9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol 2017;71:e73â€“5. European Urology, 2017, 72, e37-e38.	1.9	2
225	Considerations for standardizing predictive molecular pathology for cancer prognosis. Expert Review of Molecular Diagnostics, 2017, 17, 47-55.	3.1	3
226	Iatrogenic changes in the urinary tract. Histopathology, 2017, 70, 10-25.	2.9	25
227	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. European Urology Supplements, 2017, 16, 301-308.	0.1	6
228	Prospects for precision therapy of bladder urothelial carcinoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 261-274.	0.7	1
229	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. European Urology Supplements, 2017, 16, 232-240.	0.1	3
230	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. European Urology Supplements, 2017, 16, 223-231.	0.1	4
231	Variants of Bladder Cancer: The Pathologist's Point of View. European Urology Supplements, 2017, 16, 210-222.	0.1	16
232	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. European Urology Supplements, 2017, 16, 309-315.	0.1	10
233	Immunotherapy in genitourinary cancers: where are we going?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 73-78.	0.7	2
234	Pathology Imagebaseâ€”a reference image database for standardization of pathology. Histopathology, 2017, 71, 677-685.	2.9	19

#	Article	IF	Citations
235	MÃ¼llerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations. Clinical Genitourinary Cancer, 2017, 15, e1007-e1014.	1.9	5
236	Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy). Pathology Research and Practice, 2017, 213, 1078-1081.	2.3	10
237	Concomitant bladder cancer and prostate cancer: challenges and controversies. Nature Reviews Urology, 2017, 14, 620-629.	3.8	17
238	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. Archives of Pathology and Laboratory Medicine, 2017, 141, 1460-1461.	2.5	13
239	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912â€“4. European Urology, 2017, 71, e27-e28.	1.9	1
240	TMPRSS2â€ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. Molecular Carcinogenesis, 2017, 56, 814-820.	2.7	6
241	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738â€“9. European Urology, 2017, 71, e73-e75.	1.9	6
242	Quantitative Image Analysis on Histologic Virtual Slides for Prostate Pathology Diagnosis, Response to Chemopreventive Agents, and Prognosis. European Urology Focus, 2017, 3, 467-469.	3.1	8
243	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. Frontiers in Oncology, 2017, 7, 305.	2.8	20
244	In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 561-562.	2.8	0
245	Editorial: Emerging Biomarkers in Genitourinary Tumors. Current Drug Metabolism, 2017, 18, 690-691.	1.2	2
246	Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. Journal of Cancer, 2017, 8, 323-331.	2.5	18
247	Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction. Critical Reviews in Oncogenesis, 2017, 22, 389-401.	0.4	7
248	Epigenetic Modifications and Modulators in Prostate Cancer. Critical Reviews in Oncogenesis, 2017, 22, 439-450.	0.4	14
249	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. Oncotarget, 2017, 8, 54096-54105.	1.8	22
250	Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. Oncotarget, 2017, 8, 51522-51529.	1.8	8
251	Urinary Biomarkers for Prostate Cancer. Current Drug Metabolism, 2017, 18, 723-726.	1.2	3
252	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. Current Drug Metabolism, 2017, 18, 700-711.	1.2	25

#	Article	IF	Citations
253	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. Current Drug Metabolism, 2017, 18, 692-699.	1.2	7
254	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. Current Drug Metabolism, 2017, 18, 712-722.	1.2	31
255	Genitourinary Cancers: Molecular Determinants for Personalized Therapies. Urologia, 2016, 83, 107-109.	0.7	2
256	Prostate cancer grading in 2016. Minerva Urology and Nephrology, 2016, 69, 1-4.	2.5	0
257	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. Current Drug Targets, 2016, 17, 771-776.	2.1	20
258	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). Current Drug Targets, 2016, 17, 748-749.	2.1	4
259	Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. Advances in Anatomic Pathology, 2016, 23, 71-83.	4.3	67
260	Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3. Future Oncology, 2016, 12, 1431-1433.	2.4	5
261	Spectrum of Cystic Epithelial Tumors of the Prostate. American Journal of Surgical Pathology, 2016, 40, 886-895.	3.7	23
262	Telomerase reverse transcriptase (<scp>TERT</scp>) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Histopathology, 2016, 69, 107-113.	2.9	54
263	Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. Apmis, 2016, 124, 619-623.	2.0	6
264	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. Journal of Clinical Pathology, 2016, 69, 852-857.	2.0	29
265	Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. Journal of Clinical Pathology, 2016, 69, 547-550.	2.0	12
266	Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study. Pathology Research and Practice, 2016, 212, 471-474.	2.3	2
267	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542â€“3. European Urology, 2016, 70, e69-e70.	1.9	0
268	Handling of the Surgical Specimen and Pathology Reporting of Penile Neoplasms. , 2016, , 275-280.		0
269	Handling of the Surgical Specimen and Pathology Reporting of Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis. , 2016, , 165-170.		0
270	Cysts and Epithelial Proliferations of the Testicular Collecting System. , 2016, , 171-189.		1

#	Article	IF	Citations
271	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II Î± , survivin, and E-cadherin. Human Pathology, 2016, 57, 78-84.	2.0	24
272	Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 321-330.	2.8	58
273	Immunotargeting and personalized therapies in genitourinary cancers. Future Oncology, 2016, 12, 1853-1856.	2.4	6
274	Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand?. Expert Review of Precision Medicine and Drug Development, 2016, 1, 229-231.	0.7	4
275	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. Archives of Pathology and Laboratory Medicine, 2016, 140, 501-502.	2.5	11
276	SMARCB1/INI1 Genetic Alterations in Renal Medullary Carcinomas. European Urology, 2016, 69, 1062-1064.	1.9	17
277	Pathology and Genetics: Tumours of the Urinary System and Male Genital System. European Urology, 2016, 70, 120-123.	1.9	65
278	Intracardiac leiomyomatosis presenting as an intraoperative consultation. Pathology Research and Practice, 2016, 212, 578-581.	2.3	2
279	Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Review of Anticancer Therapy, 2016, 16, 433-440.	2.4	26
280	FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. Biomarkers in Medicine, 2016, 10, 243-253.	1.4	23
281	Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. Endocrine Pathology, 2016, 27, 123-135.	9.0	63
282	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. Molecular Diagnosis and Therapy, 2016, 20, 111-117.	3.8	77
283	Metabolic phenotype of bladder cancer. Cancer Treatment Reviews, 2016, 45, 46-57.	7.7	201
284	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912â€“4. European Urology, 2016, 70, e72-e74.	1.9	6
285	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	1.9	18
286	Metabolic Alterations in Renal and Prostate Cancer. Current Drug Metabolism, 2016, 17, 150-155.	1.2	19
287	An Overview of Emerging Immunotargets of Genitourinary Tumors. Current Drug Targets, 2016, 17, 750-756.	2.1	13
288	Emerging Immunotargets in Bladder Cancer. Current Drug Targets, 2016, 17, 757-770.	2.1	9

#	Article	IF	Citations
289	Emerging Immunotargets and Immunotherapies in Prostate Cancer. Current Drug Targets, 2016, 17, 777-782.	2.1	10
290	Urinary Bladder. , 2016, , 1681-1735.		0
291	Renal Pelvis, Ureter, and Urethra. , 2016, , 1737-1750.		0
292	Emerging molecular pathways and targets in neuroendocrine prostate cancer. Translational Cancer Research, 2016, 5, S282-S285.	1.0	2
293	Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?. Histology and Histopathology, 2016, 31, 595-600.	0.7	8
294	Re: Epithelial-to-mesenchymal Transition in Renal Neoplasms. European Urology, 2015, 68, 736-737.	1.9	10
295	Urinary bladder xanthoma: a multiâ€institutional series of 17 cases. Histopathology, 2015, 67, 255-261.	2.9	7
296	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence inâ€situ hybridization for the detection of anaplastic lymphoma kinase alterations. Histopathology, 2015, 67, 20-38.	2.9	19
297	Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies) Tj ETQq1 1 0.784314 rgBT /Ove	2.1	1
298	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	7.7	19
299	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 303-309.	1.6	16
300	The Prostate and Seminal Vesicles. , 2015, , 195-310.		1
301	Present and future of personalized medicine in adult genitourinary tumors. Future Oncology, 2015, 11, 1381-1388.	2.4	10
302	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 687-693.	2.8	13
303	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 1367-1369.	2.4	23
304	Role of STAT3 pathway in genitourinary tumors. Future Science OA, 2015, 1, FSO15.	1.9	58
305	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	2.9	41
306	A Better Understating of the Morphological Features and Molecular Characteristics of Intraductal Carcinoma Helps Clinicians Further Explain Prostate Cancer Aggressiveness. European Urology, 2015, 67, 504-507.	1.9	8

#	Article	IF	Citations
307	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. Human Pathology, 2015, 46, 1040-1044.	2.0	7
308	BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics, 2015, 15, 1201-1210.	3.1	78
309	The International Society of Urological Pathology Consensus Conference regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Revista Espanola De Patologia, 2015, 48, 90-96.	0.2	0
310	Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future Oncology, 2015, 11, 2711-2719.	2.4	5
311	The origin of prostate metastases: emerging insights. Cancer and Metastasis Reviews, 2015, 34, 765-773.	5.9	30
312	Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. Molecular Carcinogenesis, 2015, 54, 900-907.	2.7	28
313	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. European Urology, 2015, 67, 85-97.	1.9	403
314	Rare Tumors and Tumor-like Conditions in Urological Pathology. , 2015, , .		3
315	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	5.5	106
316	Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview. Current Drug Targets, 2015, 16, 96-102.	2.1	11
317	Oncotargets in Different Renal Cancer Subtypes. Current Drug Targets, 2015, 16, 125-135.	2.1	28
318	Bladder Cancer: Molecular Determinants of Personalized Therapy. Current Drug Targets, 2015, 16, 115-124.	2.1	18
319	Tumors and Tumor-Like Conditions of Urinary Bladder, Renal Pelvis, Ureter and Urethra. , 2015, , 63-194.		0
320	Prostatic and urothelial metastasis in the same lymph node: a case report. Analytical and Quantitative Cytopathology and Histopathology, 2015, 37, 139-43.	0.2	2
321	Small cell carcinoma of the prostate: molecular basis and clinical implications. Histology and Histopathology, 2015, 30, 413-24.	0.7	8
322	Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. Archivio Italiano Di Urologia Andrologia, 2014, 86, 314.	0.8	2
323	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Annals of Diagnostic Pathology, 2014, 18, 333-342.	1.3	41
324	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. Modern Pathology, 2014, 27, 1540-1548.	5.5	19

#	Article	IF	Citations
325	Re: Antibody-drug Conjugates Targeting Prostate-specific Membrane Antigen. European Urology, 2014, 66, 1190-1193.	1.9	5
326	Normal cystoscopy, malignant cytology in NMIBC: why biopsy?. Nature Reviews Urology, 2014, 11, 550-551.	3.8	2
327	Pathology of Upper Tract Urothelial Carcinoma with Emphasis on Staging. International Journal of Immunopathology and Pharmacology, 2014, 27, 509-516.	2.1	13
328	The reasons behind variation in <scp>G</scp>leason grading of prostatic biopsies: areas of agreement and misconception among 266 <scp>E</scp>uropean pathologists. Histopathology, 2014, 64, 405-411.	2.9	59
329	Prostate changes related to therapy: with special reference to hormone therapy. Future Oncology, 2014, 10, 1873-1886.	2.4	3
330	Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?. Diagnostic Pathology, 2014, 9, 190.	2.0	10
331	Best Practices Recommendations in the Application of Immunohistochemistry in the Bladder Lesions. American Journal of Surgical Pathology, 2014, 38, e20-e34.	3.7	155
332	Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology. American Journal of Surgical Pathology, 2014, 38, 1017-1022.	3.7	155
333	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. Pathology, 2014, 46, 653-655.	0.6	13
334	Tuberous Sclerosisâ€“associated Renal Cell Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1457-1467.	3.7	211
335	Primary Renal Osteosarcoma. American Journal of Clinical Pathology, 2014, 141, 747-752.	0.7	17
336	Pseudoangiosarcomatous Urothelial Carcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2014, 38, 1251-1259.	3.7	17
337	Biomarkers in bladder cancer: Translational and clinical implications. Critical Reviews in Oncology/Hematology, 2014, 89, 73-111.	4.4	88
338	Clear Cell Renal Cell Carcinoma (ccRCC) with Hemangioblastoma-like Features: A Previously Unreported Pattern of ccRCC with Possible Clinical Significance. European Urology, 2014, 66, 806-810.	1.9	20
339	Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Human Pathology, 2014, 45, 1473-1482.	2.0	110
340	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. Modern Pathology, 2014, 27, 107-112.	5.5	12
341	Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology, 2014, 64, 872-879.	2.9	52
342	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 630-637.	7.4	38

#	Article	IF	Citations
343	Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. Human Pathology, 2014, 45, 2059-2062.	2.0	10
344	Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. Diagnostic Pathology, 2014, 9, 90.	2.0	26
345	Seminal Vesicle Intraepithelial Neoplasia Versus Basal Cell Hyperplasia in a Seminal Vesicle. European Urology, 2014, 66, 623-627.	1.9	19
346	Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. Human Pathology, 2014, 45, 745-752.	2.0	6
347	A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium. Pathology, 2014, 46, 88-91.	0.6	7
348	The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder. PLoS ONE, 2014, 9, e95724.	2.5	18
349	Role of Pathology in the Multidisciplinary Management of Patients with Prostate Cancer. , 2014, , 29-41.		0
350	Contemporary update on pathology-related issues of adult renal neoplasms. Analytical and Quantitative Cytopathology and Histopathology, 2014, 36, 1-8.	0.2	2
351	Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate. Cellular Oncology (Dordrecht), 2013, 36, 37-42.	4.4	14
352	Central Prostate Pathology Review: Should It Be Mandatory?. European Urology, 2013, 64, 199-201.	1.9	23
353	Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Human Pathology, 2013, 44, 2227-2233.	2.0	45
354	Reply to JÃ©rÃ´me Verine's Letter to the Editor re: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli. Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. Eur Urol 2013;63:400â€“1. European Urology, 2013, 63, e74-e75.	1.9	0
355	Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. Modern Pathology, 2013, 26, 725-732.	5.5	88
356	Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma. Diagnostic Pathology, 2013, 8, 111.	2.0	11
357	Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 414-426.	1.6	34
358	Novel markers of squamous differentiation in the urinary bladder. Human Pathology, 2013, 44, 1989-1997.	2.0	37
359	Pathology of flat bladder lesions with emphasis on putative precursors. Diagnostic Histopathology, 2013, 19, 355-365.	0.4	4
360	Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology ofBRAFmutations. Future Oncology, 2013, 9, 245-253.	2.4	12

#	Article	IF	Citations
361	Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. European Urology, 2013, 63, 400-401.	1.9	14
362	Editorial Comment from Dr Montironi et al. to Malignant mixed epithelial and stromal tumor of the kidney: Report of the first male case. International Journal of Urology, 2013, 20, 451-452.	1.0	1
363	Reply to JÃ©rÃ´me Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4â€“related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.11.056. European Urology, 2013, 64, e53-e54.	1.9	0
364	Immunoglobulin G4â€“related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. European Urology, 2013, 64, 865-872.	1.9	23
365	Precise Morphologic Documentation with Large-format Histology of Clinical Findings in a Bladder Cancer Patient. European Urology, 2013, 64, 519-521.	1.9	2
366	Standardization of Gleason grading among 337 European pathologists. Histopathology, 2013, 62, 247-256.	2.9	148
367	Tumors of the Urinary Bladder. , 2013, , 85-100.		0
368	Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Human Pathology, 2013, 44, 164-172.	2.0	79
369	Telomere shortening distinguishes inverted urothelial neoplasms. Histopathology, 2013, 62, 595-601.	2.9	20
370	Conceptual Evolution in Cancer Biology. , 2013, , 77-109.		1
371	Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) of the Urinary Bladder With TFE3 Gene Rearrangement. American Journal of Surgical Pathology, 2013, 37, 1619-1626.	3.7	73
372	Atypical Adenomatous Hyperplasia of Prostate Lacks TMPRSS2-ERG Gene Fusion. American Journal of Surgical Pathology, 2013, 37, 1550-1554.	3.7	21
373	Somatostatin receptor expression in prostate carcinoma: the urological pathologistâ€™s role in the era of personalised medicine. Pathology, 2013, 45, 93-96.	0.6	4
374	Laser-assisted Microdissection in Translational Research. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 31-47.	1.2	63
375	Renal Tumors. American Journal of Surgical Pathology, 2013, 37, 1518-1531.	3.7	154
376	Handling and Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1505-1517.	3.7	118
377	Urethral caruncle: a lesion related to IgG4-associated sclerosing disease?. Journal of Clinical Pathology, 2013, 66, 559-562.	2.0	18
378	Prostate needle biopsy processing: a survey of laboratory practice across Europe. Journal of Clinical Pathology, 2013, 66, 120-123.	2.0	26

#	Article	IF	Citations
379	Human Papillomavirus is Not an Etiologic Agent of Urothelial Inverted Papillomas. American Journal of Surgical Pathology, 2013, 37, 1223-1228.	3.7	22
380	Synchronous Metastasis From Lobular Carcinoma and Primary Carcinoma of the Endometrium in a Patient After Tamoxifen Therapy. International Journal of Gynecological Pathology, 2013, 32, 66-70.	1.4	3
381	Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma. Histopathology, 2013, 63, 767-779.	2.9	29
382	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology, 2013, 63, 756-766.	2.9	35
383	Combined handling of prostate base/bladder neck and seminal vesicles in radical prostatectomy specimens: our approach with the whole mount technique. Histopathology, 2013, 63, 431-435.	2.9	8
384	Morphological Analysis of Radical Prostatectomy Specimens: Recent Topics Relevant to Prognosis. European Journal of Inflammation, 2013, 11, 15-22.	0.5	1
385	Treatment Effects in Prostate Cancer following Traditional and Emerging Therapies. International Journal of Immunopathology and Pharmacology, 2013, 26, 291-298.	2.1	7
386	Pathology of renal cell carcinoma: an update. Analytical and Quantitative Cytopathology and Histopathology, 2013, 35, 61-76.	0.2	9
387	Urothelial dysplasia of the bladder: diagnostic features and clinical significance. Analytical and Quantitative Cytopathology and Histopathology, 2013, 35, 121-9.	0.2	7
388	â€œNo Pay, No Playâ€•or From â€œDefensive or Passive Pathologyâ€•to â€œActive, Clinically Oriented Pathologyâ€•. Archives of Pathology and Laboratory Medicine, 2012, 136, 1474-1475.	2.5	1
389	Role of Immunohistochemistry in Diagnosing Renal Neoplasms: When Is It Really Useful?. Archives of Pathology and Laboratory Medicine, 2012, 136, 410-417.	2.5	101
390	p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Modern Pathology, 2012, 25, 1526-1533.	5.5	73
391	Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice. Expert Review of Anticancer Therapy, 2012, 12, 1371-1374.	2.4	20
392	Multilocular Cystic Renal Cell Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1425-1433.	3.7	75
393	A Contemporary Update and Pathology Reporting for Urinary Bladder Cancer. International Journal of Immunopathology and Pharmacology, 2012, 25, 565-571.	2.1	7
394	Do Not Misinterpret Intraductal Carcinoma of the Prostate as High-grade Prostatic Intraepithelial Neoplasia!. European Urology, 2012, 62, 518-522.	1.9	26
395	PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. Journal of Clinical Pathology, 2012, 65, 254-256.	2.0	37
396	Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology. Journal of Clinical Pathology, 2012, 65, 106-113.	2.0	37

#	Article	IF	Citations
397	Urethral caruncle: clinicopathologic features of 41 cases. Human Pathology, 2012, 43, 1400-1404.	2.0	49
398	Histologic grading of urothelial carcinoma: a reappraisal. Human Pathology, 2012, 43, 2097-2108.	2.0	78
399	Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis. Human Pathology, 2012, 43, 1875-1880.	2.0	15
400	Rare Lesions and Tumors of the Urinary Bladder. Selected Issues. Tumori, 2012, 98, 274-277.	1.1	2
401	Is There a Role for Prostate Tumour Overexpressed-1 in the Diagnosis of HGPIN and of Prostatic Adenocarcinoma? A Comparison with Î±-Methylacyl CoA Racemase. International Journal of Immunopathology and Pharmacology, 2012, 25, 67-74.	2.1	11
402	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	5.5	215
403	Staging of prostate cancer. Histopathology, 2012, 60, 87-117.	2.9	114
404	Re: â€œNo Pay, No Playâ€: The End of Professional Ethics in Pathology?. European Urology, 2012, 61, 424-425.	1.9	1
405	Extent of Cancer of Less Than 50% in Any Prostate Needle Biopsy Core: How Many Millimeters Are There?. European Urology, 2012, 61, 751-756.	1.9	13
406	KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. Histopathology, 2012, 61, 1036-1042.	2.9	23
407	Utility of whole slide imaging and virtual microscopy in prostate pathology. Apmis, 2012, 120, 298-304.	2.0	45
408	Unclassified renal cell carcinoma: a report of 56 cases. BJU International, 2012, 110, 786-793.	2.5	38
409	Lymphocytic vasculitis of the prostate transition zone. BJU International, 2012, 110, 1775-1780.	2.5	7
410	Rare lesions and tumors of the urinary bladder. Selected issues. Tumori, 2012, 98, 274-7.	1.1	1
411	Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7. , 2012, 34, 61-5.		3
412	Multilocular cystic renal cell neoplasms of low malignant potential. Analytical and Quantitative Cytopathology and Histopathology, 2012, 34, 235-8.	0.2	2
413	Multiplexed Methylation Profiles of Tumor Suppressor Genes in Bladder Cancer. Journal of Molecular Diagnostics, 2011, 13, 29-40.	2.8	43
414	The clinical and therapeutic implications of cancer stem cell biology. Expert Review of Anticancer Therapy, 2011, 11, 1133-1145.	2.4	24

#	Article	IF	Citations
415	The Gleason grading system: where are we now?. Diagnostic Histopathology, 2011, 17, 419-427.	0.4	3
416	The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncology, 2011, 7, 519-541.	2.4	47
417	KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients. American Journal of Pathology, 2011, 179, 540-546.	3.8	44
418	Bladder cancer: translating molecular genetic insights into clinical practice. Human Pathology, 2011, 42, 455-481.	2.0	173
419	Flat urothelial carcinoma in situ of the bladder with glandular differentiation. Human Pathology, 2011, 42, 1653-1659.	2.0	38
420	Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer.. Human Pathology, 2011, 42, 1931-1936.	2.0	14
421	Mixed Epithelial and Stromal Tumors of the Kidney. American Journal of Surgical Pathology, 2011, 35, 1114-1122.	3.7	31
422	Lymphoepithelioma-like Carcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2011, 35, 474-483.	3.7	88
423	Sarcomatoid Carcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2011, 35, e34-e46.	3.7	112
424	Cervical-type Squamous Metaplasia and Myoepithelial Cell Differentiation in Stromal Tumor of the Prostate. American Journal of Surgical Pathology, 2011, 35, 1752-1754.	3.7	8
425	Global Acetylation and Methylation Changes Predict Papillary Urothelial Neoplasia of Low Malignant Potential Recurrence: A Quantitative Analysis. International Journal of Immunopathology and Pharmacology, 2011, 24, 489-497.	2.1	7
426	Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. BJU International, 2011, 107, 532-537.	2.5	42
427	Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. BJU International, 2011, 108, 1394-1401.	2.5	49
428	Editorial Comment to When should we expect no residual tumor (pT0) once we submit incidental T1aâ€b prostate cancers to radical prostatectomy?. International Journal of Urology, 2011, 18, 153-154.	1.0	7
429	Glandular lesions of the urinary bladder:clinical significance and differential diagnosis. Histopathology, 2011, 58, 811-834.	2.9	59
430	Handling and reporting of transurethral resection specimens of the bladder in Europe: a webâ€based survey by the European Network of Uropathology (ENUP). Histopathology, 2011, 58, 579-585.	2.9	31
431	Handling of radical prostatectomy specimens: total embedding with whole mounts, with special reference to the Ancona experience. Histopathology, 2011, 59, 1006-1010.	2.9	14
432	Ectopic prostatic tissue: histogenesis and histopathological characteristics. Histopathology, 2011, 58, 750-758.	2.9	50

#	Article	IF	Citations
433	How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. Diagnostic Pathology, 2011, 6, 31.	2.0	9
434	Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited. European Urology, 2011, 59, 225-230.	1.9	23
435	Reply to Kiril Trpkov, Asli Yilmazâ€™ Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patientâ€™s Pathology and Clinical Reports. Eur Urol 2010;58:369â€“73. European Urology, 2011, 59, e7-e8.	1.9	0
436	The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management. European Urology, 2011, 60, 75-77.	1.9	9
437	Current Pathology Keys of Renal Cell Carcinoma. European Urology, 2011, 60, 634-643.	1.9	78
438	Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 175-182.	2.8	60
439	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. Cellular Oncology (Dordrecht), 2011, 34, 235-243.	4.4	8
440	Is atypical adenomatous hyperplasia of the prostate a precursor lesion?. Prostate, 2011, 71, 1746-1751.	2.3	25
441	KIT gene mutation and amplification in dysgerminoma of the ovary. Cancer, 2011, 117, 2096-2103.	4.1	85
442	The plasmacytoid carcinoma of the bladderâ€”rare variant of aggressive urothelial carcinoma. International Journal of Cancer, 2011, 129, 346-354.	5.1	94
443	ERGâ€“TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Modern Pathology, 2011, 24, 1120-1127.	5.5	130
444	Nest-Like Features in Bladder, Simulating the Nested Variant of Urothelial Carcinoma. International Journal of Surgical Pathology, 2011, 19, 11-19.	0.8	14
445	Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. Asian Journal of Andrology, 2011, 13, 242-247.	1.6	7
446	Renal Pelvis, Ureter, and Urethra. , 2011, , 1567-1579.		0
447	Urinary Bladder. , 2011, , 1515-1565.		0
448	Urothelial Carcinoma of the Bladder, Lipid Cell Variant: Clinicopathologic Findings and LOH Analysis. American Journal of Surgical Pathology, 2010, 34, 371-376.	3.7	62
449	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. American Journal of Surgical Pathology, 2010, 34, 1367-1376.	3.7	111
450	Immunohistochemical Expression and Localization of Somatostatin Receptor Subtypes in Prostate Cancer with Neuroendocrine Differentiation. International Journal of Immunopathology and Pharmacology, 2010, 23, 511-522.	2.1	22

#	Article	IF	Citations
451	Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 555-561.	2.8	17
452	Reply to JosÃ© I. LopÃ©z's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? Eur Urol 2009;56:272â€“4. European Urology, 2010, 57, e22-e23.	1.9	1
453	Re: Peripheral Zone Prostate Cancers: Location and Intraprostatic Patterns of Spread at Histopathology. European Urology, 2010, 58, 180-182.	1.9	5
454	Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors. European Urology, 2010, 58, 655-668.	1.9	84
455	Clonal origin of multifocal hepatocellular carcinoma. Cancer, 2010, 116, 4078-4085.	4.1	17
456	Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the art. Critical Reviews in Oncology/Hematology, 2010, 76, 112-126.	4.4	43
457	Histopathological findings after treatment of prostate cancer using highâ€intensity focused ultrasound (HIFU). Prostate, 2010, 70, 1196-1200.	2.3	42
458	Expression of prostate stem cell antigen in highâ€grade prostatic intraepithelial neoplasia and prostate cancer. Histopathology, 2010, 57, 572-579.	2.9	15
459	Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. BJU International, 2010, 106, 1072-1080.	2.5	11
460	Genetic profiles in renal tumors. International Journal of Urology, 2010, 17, 6-19.	1.0	10
461	Clonality andTP53Mutation Analysis of Focal Nodular Hyperplasia of the Liver. American Journal of Clinical Pathology, 2010, 134, 65-70.	0.7	8
462	Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. Expert Review of Anticancer Therapy, 2010, 10, 843-864.	2.4	34
463	Large cell undifferentiated carcinoma of the urinary bladder. Pathology, 2010, 42, 364-368.	0.6	26
464	Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. Modern Pathology, 2010, 23, 931-936.	5.5	101
465	Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Human Pathology, 2010, 41, 155-162.	2.0	86
466	Invasive micropapillary urothelial carcinoma of the bladder. Human Pathology, 2010, 41, 1159-1164.	2.0	73
467	The origins of urothelial carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 865-880.	2.4	72
468	Clinical Utility of Immunohistochemistry in the Diagnoses of Urinary Bladder Neoplasia. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 401-410.	1.2	54

#	Article	IF	Citations
469	Immunohistochemical Expression and Localization of Somatostatin Receptor Subtypes in Androgen Ablated Prostate Cancer. Analytical Cellular Pathology, 2010, 33, 27-36.	1.4	7
470	Small cell carcinoma of the urinary bladder. Histology and Histopathology, 2010, 25, 217-21.	0.7	33
471	The Pathology of Prostate Cancer. , 2010, , 45-83.		2
472	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. Analytical Cellular Pathology, 2010, 33, 27-36.	1.4	4
473	Active surveillance for low-risk prostate cancer. Anticancer Research, 2010, 30, 3683-92.	1.1	5
474	Immunohistochemical Expression of Prostate Stem Cell Antigen in Cystoprostatectomies with Incidental Prostate Cancer. International Journal of Immunopathology and Pharmacology, 2009, 22, 755-762.	2.1	15
475	Is Incidentally Detected Prostate Cancer in Patients Undergoing Radical Cystoprostatectomy Clinically Significant?. American Journal of Clinical Pathology, 2009, 131, 279-283.	0.7	55
476	Evidence for Common Clonal Origin of Multifocal Lung Cancers. Journal of the National Cancer Institute, 2009, 101, 560-570.	6.3	142
477	Molecular determinants of tumor recurrence in the urinary bladder. Future Oncology, 2009, 5, 843-857.	2.4	45
478	Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies. European Urology, 2009, 56, 105-112.	1.9	45
479	Editorial Comment on: Cytological Punctures in the Diagnosis of Renal Tumours: A Study on Accuracy and Reproducibility. European Urology, 2009, 55, 197-198.	1.9	0
480	Editorial Comment on: Platelet Microparticles: A Potential Predictive Factor of Survival in Hormone-Refractory Prostate Cancer Patients Treated with Docetaxel-Based Chemotherapy. European Urology, 2009, 56, 484-485.	1.9	0
481	Editorial Comment on: Prevalence of a Tertiary Gleason Grade and Its Impact on Adverse Histopathologic Parameters in a Contemporary Radical Prostatectomy Series. European Urology, 2009, 55, 402.	1.9	1
482	Editorial Comment on: Expression of the Endothelin Axis in Noninvasive and Superficially Invasive Bladder Cancer: Relation to Clinicopathologic and Molecular Prognostic Parameters. European Urology, 2009, 56, 846-847.	1.9	3
483	Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique. European Urology, 2009, 55, 1305-1309.	1.9	27
484	Solitary Fibrous Tumour of the Prostate Identified on Needle Biopsy. European Urology, 2009, 56, 564-567.	1.9	24
485	Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?. European Urology, 2009, 56, 272-274.	1.9	16
486	Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better. European Urology, 2009, 56, 951-955.	1.9	23

#	Article	IF	Citations
487	Decision support systems for morphologyâ€based diagnosis and prognosis of prostate neoplasms. Cancer, 2009, 115, 3068-3077.	4.1	10
488	Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. Histopathology, 2009, 55, 161-173.	2.9	40
489	TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Modern Pathology, 2009, 22, 113-118.	5.5	68
490	Staging and reporting of urothelial carcinoma of the urinary bladder. Modern Pathology, 2009, 22, S70-S95.	5.5	166
491	FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Modern Pathology, 2009, 22, 627-632.	5.5	47
492	2009 update on the classification of renal epithelial tumors in adults. International Journal of Urology, 2009, 16, 432-443.	1.0	207
493	PATHOLOGICAL DEFINITION AND DIFFICULTIES IN ASSESSING POSITIVE MARGINS IN RADICAL PROSTATECTOMY SPECIMENS. BJU International, 2009, 103, 286-288.	2.5	14
494	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. BJU International, 2009, 103, 1058-1063.	2.5	29
495	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU International, 2009, 103, 1464-1470.	2.5	94
496	Secondary neoplasms of the urinary system and male genital organs. BJU International, 2009, 104, 770-776.	2.5	72
497	Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer. Urology, 2009, 74, 385-390.	1.0	22
498	Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Human Pathology, 2009, 40, 211-217.	2.0	30
499	Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Human Pathology, 2009, 40, 10-29.	2.0	108
500	Lymphoepithelioma-like carcinoma of the prostate. Human Pathology, 2009, 40, 982-987.	2.0	25
501	Plasmacytoid urothelial carcinoma of the bladder. Human Pathology, 2009, 40, 1023-1028.	2.0	103
502	Pleomorphic giant cell carcinoma of the urinary bladder. Human Pathology, 2009, 40, 1461-1466.	2.0	50
503	2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. European Urology Supplements, 2009, 8, 453-457.	0.1	21
504	Evidence for Transformation of Fibroadenoma of the Breast to Malignant Phyllodes Tumor. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 345-350.	1.2	34

#	Article	IF	Citations
505	Implications of Cancer Stem Cells for Cancer Therapy. , 2009, , 255-262.		4
506	The European Network of Uropathology: a novel mechanism for communication between pathologists. , 2009, 31, 90-5.		3
507	Pathology of prostate cancer and focal therapy ('male lumpectomy'). Anticancer Research, 2009, 29, 5155-61.	1.1	24
508	Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis. Prostate, 2008, 68, 919-923.	2.3	29
509	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer, 2008, 112, 636-644.	4.1	41
510	Renal oncocytosis and multiple papillary adenomas with oncocytoma as dominant nodule coexisting with papillary carcinoma in a patient with diabetic glomerulosclerosis, acquired renal cystic disease and B cell lymphoma. Apmis, 2008, 116, 934-938.	2.0	9
511	Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. Modern Pathology, 2008, 21, 355-362.	5.5	33
512	Pathological variants of invasive bladder cancer according to their suggested clinical significance. BJU International, 2008, 101, 275-281.	2.5	47
513	Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU International, 2008, 102, 1369-1374.	2.5	56
514	Morphological classification and definition of benign, preneoplastic and nonâ€invasive neoplastic lesions of the urinary bladder. Histopathology, 2008, 53, 621-633.	2.9	53
515	Cystic Nephroma and Mixed Epithelial and Stromal Tumour of the Kidney: Opposite Ends of the Spectrum of the Same Entity?. European Urology, 2008, 54, 1237-1246.	1.9	65
516	Splitting and Lumping Adult Renal Epithelial Tumours: Is That What the Urologists Want?. European Urology, 2008, 53, 673-675.	1.9	5
517	Editorial Comment on: Validation of the Contemporary Epstein Criteria for Insignificant Prostate Cancer in European Men. European Urology, 2008, 54, 1311-1312.	1.9	0
518	Editorial Comment on: Prediction of Progression of Nonâ€“Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. European Urology, 2008, 54, 843-844.	1.9	2
519	â€œPathologicalâ€•Reflection on European Urology: Extended, Saturation, and Systematic Prostate Biopsies. European Urology, 2008, 53, 1111-1114.	1.9	4
520	Editorial Comment on: Comparing the Gleason Prostate Biopsy and Gleason Prostatectomy Grading System: The Lahey Clinic Medical Center Experience and an International Meta-analysis. European Urology, 2008, 54, 380-381.	1.9	0
521	Inflammatory Myofibroblastic Tumors of the Genitourinary Tractâ€”Single Entity or Continuum?. Journal of Urology, 2008, 180, 1235-1240.	0.4	81
522	Bladder cancer: Clinical and pathological profile. Scandinavian Journal of Urology and Nephrology, 2008, 42, 95-109.	1.4	79

#	Article	IF	Citations
523	Lymphatic vessel density in radical prostatectomy specimens. Human Pathology, 2008, 39, 610-615.	2.0	23
524	Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. Human Pathology, 2008, 39, 954-959.	2.0	59
525	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Seminars in Diagnostic Pathology, 2008, 25, 232-244.	1.5	9
526	Germ Cell Origin of Testicular Carcinoid Tumors. Clinical Cancer Research, 2008, 14, 1393-1396.	7.0	49
527	Histogenesis of Clear Cell Adenocarcinoma in the Urinary Tract: Evidence of Urothelial Origin. Clinical Cancer Research, 2008, 14, 1947-1955.	7.0	78
528	Identification of PMF1 Methylation in Association with Bladder Cancer Progression. Clinical Cancer Research, 2008, 14, 8236-8243.	7.0	37
529	Evidence for Polyclonal Origin of Multifocal Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2008, 14, 8087-8093.	7.0	43
530	Immunohistochemical Evaluation of Global DNA Methylation and Histone Acetylation in Papillary Urothelial Neoplasm of Low Malignant Potential. International Journal of Immunopathology and Pharmacology, 2008, 21, 615-623.	2.1	23
531	Primary Mediastinal Seminoma: A Comprehensive Assessment Integrated With Histology, Immunohistochemistry, and Fluorescence In Situ Hybridization for Chromosome 12p Abnormalities in 23 Cases. American Journal of Surgical Pathology, 2008, 32, 146-155.	3.7	71
532	Urothelial Dysplasia and Its Mimics. , 2008, 13, 149-153.		2
533	Neoplasms of the urinary bladder. , 2008, , 258-351.		25
534	Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. International Journal of Clinical and Experimental Pathology, 2008, 1, 475-88.	0.5	35
535	Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Research, 2008, 28, 2893-900.	1.1	12
536	Î±-Methylacyl Coenzyme A Racemase, Ki-67, and Topoisomerase IIÎ± in Cystoprostatectomies With Incidental Prostate Cancer. American Journal of Clinical Pathology, 2007, 128, 657-664.	0.7	25
537	Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder. Clinical Cancer Research, 2007, 13, 953-957.	7.0	76
538	Telomere Shortening and Chromosomal Abnormalities in Intestinal Metaplasia of the Urinary Bladder. Clinical Cancer Research, 2007, 13, 6232-6236.	7.0	64
539	Expression of OCT4 Transcription Factor in Cutaneous Neoplasia. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 359-362.	1.2	9
540	Urothelial Carcinoma With an Inverted Growth Pattern Can be Distinguished From Inverted Papilloma by Fluorescence In Situ Hybridization, Immunohistochemistry, and Morphologic Analysis. American Journal of Surgical Pathology, 2007, 31, 1861-1867.	3.7	82

#	Article	IF	Citations
541	Small Cell Carcinoma of the Urinary Bladderâ€"Histogenesis, Genetics, Diagnosis, Biomarkers, Treatment, and Prognosis. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 8-18.	1.2	54
542	Mechanisms of Disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nature Reviews Urology, 2007, 4, 321-332.	1.4	75
543	BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Letters, 2007, 250, 292-299.	7.2	45
544	The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Human Pathology, 2007, 38, 1207-1211.	2.0	69
545	Soft tissue tumors of the urinary bladder. Human Pathology, 2007, 38, 963-977.	2.0	79
546	Soft tissue tumors of the urinary bladder, part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. Human Pathology, 2007, 38, 807-823.	2.0	93
547	Radical prostatectomy specimen processing: A critical appraisal of sampling methods. Current Diagnostic Pathology, 2007, 13, 490-498.	0.4	5
548	Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Modern Pathology, 2007, 20, 175-182.	5.5	36
549	Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. European Urology, 2007, 52, 1682-1690.	1.9	26
550	Re: AurÃ©lien Descazeaud, Marc Zerbib, Thierry Flam et al. Can pT0 Stage of Prostate Cancer be Predicted before Radical Prostatectomy? Eur Urol 2006;50:1248â€"53. European Urology, 2007, 52, 294-295.	1.9	1
551	Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications. Pathology and Oncology Research, 2007, 13, 203-208.	1.9	10
552	Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 371-378.	2.8	41
553	Pathology of tumors of the renal pelvis and ureter and the urethra. , 2007, , 235-242.		1
554	Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Letters, 2006, 242, 266-272.	7.2	18
555	Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Human Pathology, 2006, 37, 1371-1388.	2.0	201
556	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	3.7	123
557	Prostate carcinoma I: prognostic factors in radical prostatectomy specimens and pelvic lymph nodes. BJU International, 2006, 97, 485-491.	2.5	26
558	Prostate carcinoma II: prognostic factors in prostate needle biopsies. BJU International, 2006, 97, 492-497.	2.5	37

#	Article	IF	Citations
559	The pathology of bladder cancer: an update on selected issues. BJU International, 2006, 98, 1161-1165.	2.5	14
560	Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Modern Pathology, 2006, 19, 1289-1294.	5.5	59
561	Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Modern Pathology, 2006, 19, 1395-1401.	5.5	83
562	Current practice of Gleason grading of prostate carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 111-118.	2.8	55
563	Histopathology reporting of prostate needle biopsies. 2005 update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 1-13.	2.8	20
564	The dilemma of multiorgan donors with high serum PSAâ€"a pathologistâ€™s proposal. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 273-276.	2.8	8
565	2005 Update on Pathology of Prostate Biopsies with Cancer. European Urology, 2006, 49, 441-447.	1.9	15
566	2004 WHO Classification of the Renal Tumors of the Adults. European Urology, 2006, 49, 798-805.	1.9	728
567	Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate Needle Biopsies. European Urology, 2006, 50, 666-674.	1.9	69
568	Natural history of urothelial inverted papilloma. Cancer, 2006, 107, 2622-2627.	4.1	78
569	Multilocular Cystic Renal Cell Carcinoma. American Journal of Clinical Pathology, 2006, 125, 217-222.	0.7	148
570	Macrocryosectioning and complete sampling of the prostate in a potential multiorgan donor candidate. Journal of Clinical Pathology, 2006, 60, 951-952.	2.0	4
571	Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. Journal of Clinical Pathology, 2006, 60, 332-335.	2.0	64
572	Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. Journal of Clinical Pathology, 2006, 60, 443-446.	2.0	16
573	Multilocular Cystic Renal Cell Carcinoma : A Report of 45 Cases of a Kidney Tumor of Low Malignant Potential. American Journal of Clinical Pathology, 2006, 125, 217-222.	0.7	81
574	Urinary Bladder. , 2006, , 1175-1218.		0
575	The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2005, 29, 1228-1242.	3.7	2,334
576	Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU International, 2005, 95, 1146-1152.	2.5	118

#	Article	IF	Citations
577	c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Modern Pathology, 2005, 18, 320-323.	5.5	74
578	Clonal origin of lymph node metastases in bladder carcinoma. Cancer, 2005, 104, 1901-1910.	4.1	44
579	Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis. Clinical Cancer Research, 2005, 11, 6512-6519.	7.0	160
580	Molecular Genetic Evidence for the Independent Origin of Multifocal Papillary Tumors in Patients with Papillary Renal Cell Carcinomas. Clinical Cancer Research, 2005, 11, 7226-7233.	7.0	89
581	Atypical Adenomatous Hyperplasia (Adenosis) of the Prostate: DNA Ploidy Analysis and Immunophenotype. International Journal of Surgical Pathology, 2005, 13, 167-173.	0.8	20
582	The 2004 WHO Classification of Bladder Tumors: A Summary and Commentary. International Journal of Surgical Pathology, 2005, 13, 143-153.	0.8	220
583	Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Human Pathology, 2005, 36, 718-723.	2.0	137
584	Association of human herpesvirus type 6 DNA with human bladder cancer. Cancer Letters, 2005, 230, 20-24.	7.2	13
585	Molecular Genetic Evidence for a Common Clonal Origin of Urinary Bladder Small Cell Carcinoma and Coexisting Urothelial Carcinoma. American Journal of Pathology, 2005, 166, 1533-1539.	3.8	175
586	Pleomorphic Giant Cell Carcinoma of the Prostate. Archives of Pathology and Laboratory Medicine, 2005, 129, 683-685.	2.5	46
587	Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features. , 2005, 27, 143-51.		3
588	P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. Anticancer Research, 2005, 25, 2001-4.	1.1	15
589	Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors. American Journal of Clinical Pathology, 2004, 122, 444-452.	0.7	74
590	Handling and Pathology Reporting of Specimens with Carcinoma of the Urinary Bladder, Ureter, and Renal Pelvis. European Urology, 2004, 45, 257-266.	1.9	108
591	Non-Invasive Urothelial Neoplasms: According to the Most Recent WHO Classification. European Urology, 2004, 46, 170-176.	1.9	155
592	Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 103-10.	2.8	26
593	Small cell carcinoma of the urinary bladder. Cancer, 2004, 101, 957-962.	4.1	268
594	Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors The Role of G 1 -S Modulators (p53, P21Waf1, p27Kip1, Cyclin D1, and Cyclin D3), Proliferation Index and Clinicopathologic Parameters. American Journal of Clinical Pathology, 2004, 122, 444-452.	0.7	41

#	Article	IF	Citations
595	Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology, 2003, 35, 484-491.	0.6	59
596	Inflammatory Myofibroblastic Tumors of the Kidney: A Clinicopathologic and Immunohistochemical Study of 12 Cases. American Journal of Surgical Pathology, 2003, 27, 658-666.	3.7	96
597	Sclerosing Adenosis of the Prostate. Archives of Pathology and Laboratory Medicine, 2003, 127, e14-e16.	2.5	24
598	Evaluation of Prognostic Factors in Radical Prostatectomy Specimens with Cancer. Urologia Internationalis, 2002, 68, 209-215.	1.3	13
599	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 3-11.	2.8	102
600	Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 552-557.	2.8	101
601	BLADDER TREATMENT. Urologic Clinics of North America, 1999, 26, 535-554.	1.8	24
602	Neonatal exposure of male rats to estradiol benzoate causes rete testis dilation and backflow impairment of spermatogenesis. , 1998, 252, 17-33.		46
603	Prostatic adenocarcinoma with glomeruloid features. Human Pathology, 1998, 29, 543-546.	2.0	44
604	Intestinal metaplasia is not a strong risk factor for bladder cancer: Study of 53 cases with long-term follow-up. Urology, 1997, 50, 427-431.	1.0	103
605	Virilizing mature ovarian cystic teratomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 431, 149-151.	2.8	18
606	Ultrastructure of prostatic intraepithelial neoplasia. , 1997, 33, 32-37.		19
607	Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. American Journal of Surgical Pathology, 1997, 21, 931-935.	3.7	60
608	Lipomatous Hypertrophy of the Cardiac Interatrial Septum. American Journal of Forensic Medicine and Pathology, 1997, 18, 206-207.	0.8	0
609	Vasculitis Involving the Prostate. , 1996, 1, 70-73.		4
610	Molecular biology of prostatic intraepithelial neoplasia. , 1996, 29, 117-134.		178
611	Workgroup 5: Assessment of prostate carcinoma in core needle biopsy--Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer, 1996, 78, 376-381.	4.1	90
612	Workgroup 5: Assessment of prostate carcinoma in core needle biopsyâ€â€Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer, 1996, 78, 376-381.	4.1	4

#	Article	IF	Citations
613	Inflammatory Pseudotumor of the Urinary Bladder. Urologia Internationalis, 1995, 55, 173-176.	1.3	25
614	Downregulation of FcÎ³ Receptor IIIAÎ± (CD16-II) on Natural Killer Cells Induced by Anti-CD16 mAb Is Independent of Protein Tyrosine Kinases and Protein Kinase C. Cellular Immunology, 1994, 158, 208-217.	3.0	41
615	Prognostic factors in survival of bladder cancer. Cancer, 1992, 70, 799-807.	4.1	26
616	Evolution of extramedullary plasmacytoma in a patient with primary SjÃ¶gren's syndrome. Arthritis and Rheumatism, 1990, 33, 150-151.	6.7	9
617	T-Zone Histiocytes and Recurrence of Papillary Urothelial Bladder Carcinoma. Urologia Internationalis, 1989, 44, 205-209.	1.3	15